Biologic Therapeutics Market Size to grow by USD 398.3 billion between 2024-2028
According to a research report “ Biologic Therapeutics Market” by Application (Cancer, Infectious diseases, Autoimmune diseases, Others) Product (Antibody therapeutics, Vaccines, Cell therapy, Gene therapy, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 398.3 billion, at a CAGR of 13.64% during the forecast period. Biologic therapeutics, including complex proteins and monoclonal antibodies, have revolutionized healthcare by providing effective treatments for various chronic conditions. Biosimilars, as biologically similar alternatives to original biologic drugs, offer significant potential for the market. Developed using distinct production methods or cell lines, biosimilars exhibit comparable safety, purity, and potency to their reference products. Their introduction fosters competition, driving market growth, and reduces treatment costs. By expanding access to these life-saving medications, biosimilars contribute to improved patient outcomes and reduced healthcare expenses, which is crucial given the escalating healthcare expenditures..
Browse market data tables, figures, and in-depth TOC on “Biologic Therapeutics Market” by Application (Cancer, Infectious diseases, Autoimmune diseases, Others) Product (Antibody therapeutics, Vaccines, Cell therapy, Gene therapy, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Application, the Cancer segment is projected to dominate the market size in 2024
In the realm of oncology, biologic therapeutics represent a significant advancement in cancer treatment. These therapies target cancer cells, which exhibit uncontrolled division and form tumors by losing the characteristic of contact inhibition. Biologics differ from traditional chemotherapeutic agents in their mode of action, as they primarily affect cancer cells while minimizing impact on healthy cells. Biologics encompass two primary mechanisms: direct and indirect. Direct action involves the elimination of cancer cells, while indirect action stimulates the immune system to destroy cancer cells. The first oncology biologic approved by the US Food and Drug Administration (FDA) was the bacillus Calmette-Guerin (BCG) vaccine. This pioneering development marked a milestone in cancer treatment, paving the way for targeted therapies with fewer side effects compared to chemotherapeutics.
By Product, Antibody therapeutics segment is expected to hold the largest market size for the year 2024
The antibody therapeutics segment, which includes monoclonal antibodies, dominates the global biologic therapeutics market due to their high specificity and efficacy. Monoclonal antibodies, derived from single-parent cells, have revolutionized the pharmaceutical industry with their ability to target specific receptors on cells. Over the past five years, they have emerged as the best-selling drugs, accounting for a significant market share. Their specificity in action makes monoclonal antibodies more effective than conventional treatments for various immunological and chronic conditions, particularly cancer. Despite some adverse effects, the market growth for antibody therapeutics is robust, driven by their potential to offer superior clinical outcomes.
North America is forecasted to hold the largest market size by region in 2024
The Biologic Therapeutics Market represents a significant and growing sector in the healthcare industry. These advanced treatments utilize living cells or biological molecules to address various medical conditions. Market expansion is driven by increasing prevalence of chronic diseases, regulatory approvals, and technological advancements. Companies are investing heavily in research and development to bring innovative solutions to market, ensuring continued growth in this sector.
The Biologic Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Biologics Market encompasses a range of therapeutic modalities, including molecular therapies such as RNAi and antisense, recombinant proteins, vaccines, monoclonal antibodies (MAbs), and more. These advanced therapies offer new hope for the treatment of chronic diseases and non-communicable diseases (NCDs), including lung cancer, breast cancer, Parkinson's disease, and Alzheimer's disease. Molecular therapies like Tezepelumab for asthma and mRNA-based vaccines for COVID-19 are revolutionizing the healthcare landscape. Companies like CanSino Biologics are at the forefront of microbial-based biologic production, ensuring affordable and accessible treatments for patients. The Biologics Market faces stringent regulatory processes, ensuring safety and efficacy. The FDA's approval of Leqembi (lecanemab-irmb) for Alzheimer's disease marks a significant milestone in personalized medicine. Diagnostics play a crucial role in the Biologics Market, with companion diagnostics enabling precise treatment plans based on individual genetic profiles. Autoimmune diseases and genetic diseases are also targeted by biologic therapies, offering hope for millions of patients worldwide. According to Globocan, cancer remains a leading cause of death, underscoring the need for continued innovation in the Biologics Market. The future holds promise with ongoing research and development in this dynamic field.
Market Research Overview
The Biologic Therapeutics Market encompasses a wide range of medical treatments derived from biotechnology, including recombinant interferons, platelet-derived growth factors, and biologic response modifiers like anti-cytokine therapies and Antithymocyte Globulin (ATG). These therapies target various diseases, from cancers to infectious diseases, using proteins, cell lines, and biomedical science techniques. Key products include Enbrel, Rituxan/MabThera, Avastin, Herceptin, Humira, Remicade, and various biosimilars. Newer technologies like mRNA therapeutics, nanosystems, adjuvants, and protein purification are also driving growth. Companies like CanSino Biologics, BioMarin, CSL Behring, and Pfizer are leading the charge in this field, producing treatments for chronic diseases, hematological disorders, and oncology. Microbial-based biologic production, using organisms like HEK and CHO, is another significant area. Monoclonal antibodies (MAbs), mRNA-1273, Tezepelumab, and various vaccines for cancers (Prostate, Colorectal, Lung, Breast), infectious diseases (Flu, RSV), and chronic diseases (Parkinson's, Alzheimer's) are under development. Stringent regulatory processes ensure safety and efficacy, with FDA approval for various treatments like Aimovig, Kadycla, Shingrix, Adcetris, Perjeta, and Leqembi (lecanemab-irmb). Companion diagnostics and personalized medicine are also gaining importance in this market. Autoimmune diseases and genetic diseases are other areas of focus.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
